Schizophrenia Spectrum Biomarkers Consortium: Establishment of a Biorepository for the Discovery of Quantitative Fluid Biomarkers
Schizophrenia Bulletin · 2026
DOI: 10.1093/schbul/sbag113 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Schizophrenia Bulletin, 2026. Verfasst von Mohini Ranganathan und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06511, United States. Hauptthemen laut MEDLINE: Schizophrenia, Biological Specimen Banks, Psychotic Disorders. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Stanley Center for Psychiatric Research.
Abstract (Originalsprache)
Background and Hypothesis Schizophrenia spectrum disorders (SSDs) produce severe symptoms, disability, and premature mortality, but only partially effective symptomatic treatments exist. Treatment development is impeded by lack of insight into disease mechanisms or objective biomarkers for clinical trials. Advances in genetics and neurobiology have converged on strong pathogenic hypotheses for SSDs centered on synapse dysfunction and excessive pruning, pathogenic processes that may produce measurable proteomic evidence in cerebrospinal fluid (CSF). Leveraging design precedents from successful fluid biomarkers discovery for Alzheimer’s disease, we undertook a pilot study to test the feasibility of repeated CSF and blood samples collection from individuals with SSDs. Here we report on successful implementation of longitudinal bio-behavioral phenotyping in SSDs and establishment of a repository to permit broad sample and data sharing. Study Design The Schizophrenia Spectrum Biomarkers Consortium (SSBC) study principles included longitudinal study design, paired CSF and plasma collection associated with robust phenotypic characterization, at 3 academic sites and the establishment of a biorepository. Participants underwent clinical and cognitive assessments, neuroimaging, blood draws, and CSF collection via lumbar puncture (LP) every 6 months. Study Results SSBC successfully enrolled 48 SSD and 41 Healthy Controls with a 73% longitudinal retention. Clinical, cognitive, and neuroimaging results were consistent across sites and with existing studies. Study procedures were well tolerated, and almost all LPs (99%) resulted in either no or minor headache/backache that resolved without medical interventions. Conclusions The pilot SSBC study demonstrates that a multi-site, longitudinal study with repeat CSF collection is feasible, with excellent participant acceptability and retention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06511, United States.
- VA Connecticut Healthcare System, West Haven, CT 06516, United States.
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, United States.
- Neurodevelopment and Psychosis Section, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, United States.
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
- Department of Psychology, Clark University, Worcester, MA 01610, United States.
ORCID-Profile: Mohini Ranganathan, Monica E Calkins
Förderung
- Stanley Center for Psychiatric Research
Zitieren
APA
Ranganathan, M., Jakob, S., Cerrato, F., Urban Spillane, L., Daryoush, T. S., Shuster, S., Dokholyan, K., Herrera, S., Koo, B. B., Markowitz, C., Deng, P., Rush, S., Calkins, M. E., Troyan, S., Ruparel, K., Gur, R. C., Reynolds, H., Wegel, C., Johnson, M. B., …, & Hyman, S. E. (2026). Schizophrenia Spectrum Biomarkers Consortium: Establishment of a Biorepository for the Discovery of Quantitative Fluid Biomarkers. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbag113
Vancouver
Ranganathan M, Jakob S, Cerrato F, Urban Spillane L, Daryoush TS, Shuster S, et al. Schizophrenia Spectrum Biomarkers Consortium: Establishment of a Biorepository for the Discovery of Quantitative Fluid Biomarkers. Schizophrenia Bulletin. 2026. doi:10.1093/schbul/sbag113
BibTeX
@article{Ranganathan2026,
author = {Ranganathan, Mohini and Jakob, Susanne and Cerrato, Felecia and Urban Spillane, Lia and Daryoush, Tarlan S and Shuster, Sophie and Dokholyan, Katherine and Herrera, Shaynna and Koo, Brian B and Markowitz, Clyde and Deng, Pojen and Rush, Sage and Calkins, Monica E and Troyan, Scott and Ruparel, Kosha and Gur, Ruben C and Reynolds, Holly and Wegel, Claire and Johnson, Matthew B and Hom, Lauren and Bryant, Sam and Mair, Ross W and Buckner, Randy L and Psychiatry Biomarkers Network (PBN) Consortium, Psychiatry Biomarkers Network (PBN) Consortium and Birnbaum, Rebecca and Birnbaum, Rebecca and Kohler, Christian G and Corcoran, Cheryl M and Gur, Raquel E and Hyman, Steven E},
title = {Schizophrenia Spectrum Biomarkers Consortium: Establishment of a Biorepository for the Discovery of Quantitative Fluid Biomarkers},
journal = {Schizophrenia Bulletin},
year = {2026},
doi = {10.1093/schbul/sbag113}
}
EUVIMED